It ensures any stray cancer cells left after surgery don’t continue to grow. Second, capecitabine can be used ... at some of the most common. First-line chemotherapy for gallbladder cancer ...

The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for ... including tumor cells in ascites or microscopic evidence ...

There were no cases of red cell fragmentation requiring cessation ... the median survival of patients receiving capecitabine/MMC third-line was consistent with that observed for oxaliplatin ...

Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy ...

In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen ...

The body changes capecitabine into a common chemotherapy drug called fluorouracil. It stops cells from making and repairing DNA ... You should contact your advice line urgently if you think you have ...

Most trials of first-line chemotherapy for advanced breast ... one assigned continuous capecitabine had her diagnosis changed from metastatic breast cancer to non–small-cell lung cancer after random ...

We evaluated capecitabine (an oral fluoropyrimidine ... if they had a histologically proven adenocarcinoma, squamous-cell carcinoma, or undifferentiated carcinoma of the esophagus ...

Take capecitabine tablets morning and evening. You have blood tests before and during your treatment. They check your levels of blood cells and other substances ... You should contact your advice line ...

To address this, researchers developed a "cell line atlas," which is a collection of cancer cell lines—each derived from an individual patient's tumor and adapted to grow in the lab—with ...

Because there was likely to have been considerable overlap between these 2 groups (and perhaps total overlap, as assumed by the manufacturer), a significant percentage of patients (up to 37%) could ...